Consistent with the cellular data, trametinib and PIK93 treatment alone slowed tumor growth in KRAS-mutant tumors, and the drug combination further inhibited tumor growth (Supplementary information, Fig. S4c–h). This evidence concerns the gene KRAS and neoplasm.